ストックスクリーナーアプリを入手
30.99
1.91%
0.58
前日終値:
$30.41
開ける：
$30.41
24時間の取引高:
737.17K
Relative Volume:
0.93
時価総額：
$2.90B
収益：
$4.72M
当期純損益:
$-277.91M
株価収益率:
-8.3083
EPS:
-3.73
ネットキャッシュフロー:
$-203.56M
1週間 パフォーマンス:
-0.39%
1か月 パフォーマンス:
+1.91%
6か月 パフォーマンス:
-20.11%
1年 パフォーマンス:
-41.90%
1日の値動き範囲:
$29.72
$31.50
1週間の範囲:
$29.72
$31.89
52週間の値動き範囲:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
名前
Crinetics Pharmaceuticals Inc
セクター
電話
858-450-6464
住所
6055 LUSK BLVD., SAN DIEGO, CA
CRNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
30.99 | 2.85B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 開始されました | Goldman | Neutral |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-11 | 開始されました | TD Cowen | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Peer Perform |
| 2025-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-01-16 | 開始されました | Morgan Stanley | Overweight |
| 2023-12-21 | 開始されました | Jefferies | Hold |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 開始されました | Oppenheimer | Outperform |
| 2023-04-24 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Robert W. Baird | Outperform |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-23 | 開始されました | Evercore ISI | Outperform |
| 2021-06-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 開始されました | ROTH Capital | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-13 | 開始されました | JP Morgan | Neutral |
| 2018-08-13 | 開始されました | Leerink Partners | Outperform |
| 2018-08-13 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionElite Investor Club - Metal.it
What analysts say about Crinetics Pharmaceuticals Inc. stockFree Investment Case Studies - PrintWeekIndia
Victory Capital Management Inc. Trims Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics’ 48% decline validates InvestingPro’s October 2024 overvalued call By Investing.com - Investing.com UK
Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Price Target at $69.50 - Defense World
What drives Crinetics Pharmaceuticals Inc. stock priceAccelerated earnings growth - Autocar Professional
Is Crinetics Pharmaceuticals Inc. a good long term investmentStrong return on assets - jammulinksnews.com
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - MSN
Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders - BioWorld MedTech
Crinetics stock rating reiterated by Piper Sandler ahead of PALSONIFY PDUFA - Investing.com Canada
H.C. Wainwright reiterates Buy rating on Crinetics stock at $81 price target - Investing.com Canada
Crinetics Pharmaceuticals’ Palsonify Gains Positive Endorsement for Acromegaly Treatment with Promising Pipeline Expansion - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Arizona State Retirement System - Defense World
The week in pharma: action, reaction and insight – week to July 18 - The Pharma Letter
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Xponance Inc. - Defense World
Crinetics Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity gains - jammulinksnews.com
Crinetics Pharmaceuticals’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada
How Crinetics Pharmaceuticals Inc. stock performs during market volatilityFree Signals Group - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria
Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - inkl
Crinetics reveals new data from acromegaly therapy programme - Yahoo Finance
New data for oral acromegaly drug ahead of approval decision - The Pharma Letter
Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest
Crinetics Pharmaceuticals Inc (CRNX) 財務データ
収益
当期純利益
現金流量
EPS
Crinetics Pharmaceuticals Inc (CRNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Betz Stephen F. | Chief Scientific Officer |
Jun 12 '25 |
Sale |
32.23 |
97,483 |
3,141,877 |
99,713 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):